ABBV
AbbVie Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$286.00
−0.98%Price chart
Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3
Key dataNov 3, 2026
Open$288.42
From 52W high−3.01%
Volume5.34M
Market cap$505.40B
P/E (TTM)49.1x
P/S (TTM)7.7x
Div yield2.42%
Key dataNov 3, 2026
Open
$288.42
From 52W high
−3.01%
Volume
5.34M
Market cap
$505.40B
ValuationView details →
P/E (Fwd)
18.2x
EV/EBITDA
—
P/E (TTM)
49.1x
RSI (14)
62.3
MomentumView details →
1D Return
−0.98%
YTD Return
+26.48%
SummaryUpdated Sep 1, 2026
AbbVie Inc. (NYSE:ABBV) is a pharmaceutical company that was spun off from Abbott Laboratories in 2013. The company emerged as an independent entity to focus exclusively on research-based pharmaceuticals, inheriting Abbott's established drug portfolio including the blockbuster immunology drug Humira. Since its inception, AbbVie has evolved from a company heavily dependent on a single product to a diversified pharmaceutical enterprise with a robust pipeline across multiple therapeutic areas. Today, AbbVie operates as one of the world's largest biopharmaceutical companies, with operations spanning immunology, oncology, neuroscience, and aesthetics.
Similar companies
Latest newsMore news →
Nxera Pharma UK Ltd. entered an exclusive global license agreement with AbbVie for Nxera's EP4 agonist program, including NXE0033744, for an upfront payment of US$100 million.7h agoAbbVie Inc. expanded its Oxford research and development facility as part of an investment exceeding £120 million.14h ago